Posted on May 28, 2019 by Sitemaster
Whether whole pelvic radiation therapy (WPRT) is beneficial for men newly diagnosed with Gleason grade 9/10 (Grade Group 5) is controversial. … READ MORE …
Filed under: Diagnosis, Management, Risk, Treatment | Tagged: 10, 9, Gleason, pelvic, primary, radiation, score, whole | 1 Comment »
Posted on May 23, 2019 by Sitemaster
A couple of weeks ago (see here) we had first told you about the launch of the new PCa Social Network PLUS app that allows mobile access to a new social netowrk (and a clinical trial of its effects) for men with prostate cancer. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk, Treatment | Tagged: app, mobile, netwrok, PCa Social Network PLUS, social, trial | 4 Comments »
Posted on May 18, 2019 by Sitemaster
We have noted several times in the past that, at least to date, compared to the results shown by the PD-1 and PD-L1 checkpoint inhibitors in the treatment of cancers like lung cancer, kidney cancer, and melanoma, there has been little evidence of the value of these agents in the treatment of advanced prostate cancer. … READ MORE …
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: atezolizumab. Keytruda, HSPC, mCRPC, nivolumab, Opdivo, PD-1, PD-L1, pembrolizumab, Tecentriq | 7 Comments »
Posted on May 17, 2019 by Sitemaster
The first iteration of the Advanced Prostate Cancer Consensus Conference (APCCC) was held in St. Gallen, Switzerland, in 2017, and the second iteration is upcoming in late August this year — this time in Basel. … READ MORE …
Filed under: Management, Treatment | Tagged: advanced, APCCC, consensus, controversy, resolution | 1 Comment »
Posted on May 15, 2019 by Sitemaster
The American Society of Clinical Oncology (ASCO) has just released the abstracts of papers to be presented at the upcoming annual meeting in Chicago, starting on Friday, May 31. … READ MORE …
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: 2019, abstract, ASCO | 9 Comments »
Posted on May 11, 2019 by Sitemaster
The results of the 1,125-patient, randomized, double-blind ENZAMET trial are to be reported in a late-breaking abstract at the upcoming annual meeting of the American Society for Clinical Oncology (ASCO) in Chicago. … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: abiraterone, ENZAMET, enzlutamide, hormone-sensitive, latitude, metastatic, mHSPC, outcome | 9 Comments »
Posted on April 30, 2019 by Sitemaster
According to a media release issued yesterday by Johnson & Johnson, its Janssen Pharmaceuticals division has just submitted an application to the U.S. Food and Drug Administration for the approval of apalutamide (Eleada) in the treatment of men with metastatic, castration-sensitive prostate cancer (mCSPC). … READ MORE …
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: apalutamide, approval, castration-sensitive, mCSPC, metastatic, trial, TRITON | 3 Comments »
